Luminopia

Luminopia is a commercial-stage digital therapeutics company focused on revolutionizing amblyopia treatment. Its FDA-cleared, binocular therapy replaces traditional patching with an engaging one-hour daily regimen where children watch their favorite shows through a specialized VR headset, leading to high compliance and significant vision improvement. Backed by clinical data from a pivotal trial and a real-world registry, Luminopia has established a prescription-based business model and partnerships with major entertainment companies. The company is positioned to address a large pediatric market with a first-in-class product that improves both clinical outcomes and patient experience.

A prescription digital therapeutic platform using a virtual reality headset to deliver modified, dichoptic visual content (TV shows/movies) to treat amblyopia by promoting binocular vision.

Luminopia's primary competition is the entrenched standard of care: patching and atropine drops. It also faces emerging competition from other digital therapeutic companies developing binocular treatments, such as CureSight by NovaSight (FDA-cleared) and Vivid Vision (used in clinics). Its first-mover FDA advantage and engaging content library are key differentiators.